263 related articles for article (PubMed ID: 14978882)
21. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
Shao B; Gao YR; Wang C; Yan SK; Cai Q; Jiang JL; Yang J; Bai HT; Zhao M; Zhao CX
Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Marcucci G; Mrózek K; Ruppert AS; Maharry K; Kolitz JE; Moore JO; Mayer RJ; Pettenati MJ; Powell BL; Edwards CG; Sterling LJ; Vardiman JW; Schiffer CA; Carroll AJ; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Aug; 23(24):5705-17. PubMed ID: 16110030
[TBL] [Abstract][Full Text] [Related]
23. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.
Schlenk RF; Benner A; Krauter J; Büchner T; Sauerland C; Ehninger G; Schaich M; Mohr B; Niederwieser D; Krahl R; Pasold R; Döhner K; Ganser A; Döhner H; Heil G
J Clin Oncol; 2004 Sep; 22(18):3741-50. PubMed ID: 15289486
[TBL] [Abstract][Full Text] [Related]
24. Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia.
Rodriguez CP; Baz R; Jawde RA; Rybicki LA; Kalaycio ME; Advani A; Sobecks R; Sekeres MA
Leuk Res; 2008 Mar; 32(3):413-20. PubMed ID: 17727945
[TBL] [Abstract][Full Text] [Related]
25. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
26. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
[TBL] [Abstract][Full Text] [Related]
27. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
Sperr WR; Piribauer M; Wimazal F; Fonatsch C; Thalhammer-Scherrer R; Schwarzinger I; Geissler K; Knöbl P; Jäger U; Lechner K; Valent P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3965-71. PubMed ID: 15217926
[TBL] [Abstract][Full Text] [Related]
28. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.
Kalaycio M; Advani A; Pohlman B; Sekeres M; Tripp B; Rybicki L; Sobecks R
Am J Hematol; 2008 Nov; 83(11):831-4. PubMed ID: 18756545
[TBL] [Abstract][Full Text] [Related]
29. Acute leukemia in patients sixty years of age and older: a twenty year single institution review.
Leger CS; Leitch HA; Galbraith PF; Li CH; Vickars LM
Am J Clin Oncol; 2009 Apr; 32(2):137-41. PubMed ID: 19307947
[TBL] [Abstract][Full Text] [Related]
30. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.
Brunet S; Esteve J; Berlanga J; Ribera JM; Bueno J; Martí JM; Bargay J; Guardia R; Juliá A; Granena A; Montserrat E; Sierra J;
Haematologica; 2004 Aug; 89(8):940-9. PubMed ID: 15339677
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of prognostic variables in childhood acute myeloid leukemia].
Gu LJ; Tie LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Ye H; Wang YP; Dong L
Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):10-3. PubMed ID: 16732931
[TBL] [Abstract][Full Text] [Related]
32. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
Giles F; Rizzieri D; Karp J; Vey N; Ravandi F; Faderl S; Khan KD; Verhoef G; Wijermans P; Advani A; Roboz G; Kantarjian H; Bilgrami SF; Ferrant A; Daenen SM; Karsten V; Cahill A; Albitar M; Mufti G; O'Brien S
J Clin Oncol; 2007 Jan; 25(1):25-31. PubMed ID: 17146105
[TBL] [Abstract][Full Text] [Related]
33. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
[TBL] [Abstract][Full Text] [Related]
34. The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.
Cook G; Clark RE; Crawley C; Mackinnon S; Russell N; Thomson K; Pearce RM; Towlson K; Marks DI
Biol Blood Marrow Transplant; 2006 Mar; 12(3):293-300. PubMed ID: 16503498
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic value of early treatment response in children with acute myeloid leukemia].
Tie LJ; Gu LJ; Song DL; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J; Wang YP; Zou JY
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(26):1837-40. PubMed ID: 17054861
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of elderly patients with acute myeloid leukemia].
Löwenberg B
Ned Tijdschr Geneeskd; 1997 Nov; 141(45):2157-9. PubMed ID: 9550795
[TBL] [Abstract][Full Text] [Related]
37. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation.
Yoshimoto G; Nagafuji K; Miyamoto T; Kinukawa N; Takase K; Eto T; Kato K; Hayashi S; Kamimura T; Ohno Y; Taniguchi S; Harada M
Bone Marrow Transplant; 2005 Dec; 36(11):977-83. PubMed ID: 16184177
[TBL] [Abstract][Full Text] [Related]
38. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
[TBL] [Abstract][Full Text] [Related]
39. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Büchner T; Berdel WE; Haferlach C; Haferlach T; Schnittger S; Müller-Tidow C; Braess J; Spiekermann K; Kienast J; Staib P; Grüneisen A; Kern W; Reichle A; Maschmeyer G; Aul C; Lengfelder E; Sauerland MC; Heinecke A; Wörmann B; Hiddemann W
J Clin Oncol; 2009 Jan; 27(1):61-9. PubMed ID: 19047294
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
Rizzieri DA; O'Brien JA; Broadwater G; Decastro CM; Dev P; Diehl L; Beaven A; Lagoo A; Gockerman JP; Chao NJ; Moore JO
Cancer; 2009 Jul; 115(13):2922-9. PubMed ID: 19452542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
